FDA panel to discuss Zavesca, Carbaglu

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Jan. 12 to discuss an sNDA from Actelion Ltd. (SIX:ATLN) for Zavesca miglustat to treat progressive neurological manifestations in patients with Niemann-Pick type C disease, a lysosomal storage disease. The oral N-butyldeoxynojirimycin glucosyltransferase inhibitor is already approved to treat Type I Gaucher's disease. Actelion was up CHF0.10 to CHF58.45 on Wednesday. ...